Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 16/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582814 | 0.83 | NPC1 (0.43) | S1PR4NPC1LMNAMAPTHPGD | |
| SCHEMBL8561264 | 0.82 | S1PR4 (0.39) | S1PR4PLAUNPC1LMNAMAPT | |
| SCHEMBL2657961 | 0.81 | S1PR4 (0.41) | S1PR4PLAUNPC1LMNAMAPT | |
| SCHEMBL16235378 | 0.77 | GAA (0.40) | S1PR4NPC1LMNAMAPTHPGD | |
| SCHEMBL18839589 | 0.77 | PLAU (0.41) | S1PR4PLAULMNAMAPT | |
| SCHEMBL2657236 | 0.76 | MAPT (0.46) | S1PR4NPC1LMNAMAPTHPGD | |
| SCHEMBL2338881 | 0.74 | KMT2A (0.53) | S1PR4PLAUNPC1MAPTCTDSP1 | |
| SCHEMBL2659190 | 0.73 | SLC6A4 (0.44) | S1PR4NPC1LMNAMAPTHPGD | |
| SCHEMBL6436859 | 0.73 | PLAU (0.60) | S1PR4PLAUL3MBTL1 | |
| SCHEMBL3142475 | 0.73 | S1PR4 (0.63) | S1PR4NPC1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420642-B2 | Pyridine derivatives useful as glucokinase activators | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2195312-B1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20100216794-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-2195312-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009046784-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216794-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | HK1, GCKR, GCK | S1PR4 3995/4885PLAU 1952/4885NPC1 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.